Insights
Capturing Patients Diversity as the Next Challenge in Drug Development? Insights from IASP 2024
Earlier this month, the IASP (International Association for the Study of Pain) meeting marked a significant moment in honoring the vision of Professor John Bonica founder of IASP. In 1973, Professor Bonica successfully convened a group of experts in Issaquah, Washington, to chart a path forward for improving the lives of patients suffering from pain.
Read MoreHow Cognivia Turns Traits Into Data with a Validated Questionnaire & Machine Learning
Learn more about the development of the MPsQ and the its use as part of the Placebell©™ technology.
Read MorePain: the Tree that Hides the Forest of Symptoms
The 2024 International Osteoarthritis Research Society (OARSI) conference concluded last week, offering valuable exchange and information. What insights could we gather from these dynamic four days? One of the most interesting themes was the relationship between patients’ osteoarthritis (OA), pain, and psychosocial state – a crucial but often overlooked topic. Indeed, OA studies typically assess
Read MoreGlobal Reach, Local Understanding: Cognivia’s Participant Questionnaire Validated in Over 50 Languages for Comprehensive Clinical Trials
For high quality clinical trial data, the voice of the participant (i.e. patient and/or caregiver) must be captured in the language that they can understand. In this blog post, we discuss the linguistic validation process of the participant questionnaire behind Cognivia’s clinical trial technology.
Read MoreExpectations of Improvement in Clinical Trials: site or patient related?
There are multiple techniques to account for these expectations in studies, including site stafftraining, subject training before the start of the study, and applying an adjustment covariate.
Read MoreThe FDA highlights the tools to enhance the precision of primary analyses in clinical trials.
The FDA released its final guidance regarding the use of covariates to improve the precision of statistical analyses in clinical trials on 26 May 2023. It is a major step forward in the statistical analysis of clinical trial data. Recognizing that nearly a decade ago, the publication of the EMA guide initiated the movement, the FDA has crystallized the concept with the current guidance.
Read More